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Abstract
Nitrosative stress, where nitrosylation of tyrosine (Tyr) leading to 3-nitrotyrosine proteins or free 3-nitrotyrosine is
the most prominent change, has been proposed as a pathogenic mechanism in Parkinson’s disease (PD). Levels of
3-nitrotyrosine proteins in serum and cerebrospinal fluid (CSF) of patients with PD have not been studied. Ni-
trosative stress-induced protein changes in serum and CSF were analyzed in patients with PD (n= 54) and controls
(n= 40). Herein, we demonstrate the presence of nitrosative stress in serum and CSF of patients with early PD
leading to selective increase of 3-nitrotyrosine proteins other than nitroalbumin, without free 3-nitrotyrosine
(Hoehn-Yahr stage 1, p< 0.05; stage 2, p< 0.01). Among 3-nitrotyrosine proteins, nitro-a-synuclein (N-aSyn) was
detected in serum, not CSF, and the sites of Tyr nitrosylation were observed to be modified in patients with early
PD. Thus, the intensity of nitrosylation of Tyr125/136 residues is enhanced (stage 1, p< 0.05; stage 2, p< 0.01), and
that of the Tyr39 site is reduced (stage 1, p< 0.05), and the ratio between both parameters (a-synuclein with
nitrosylated tyrosines 125 and 136 [N-aSyn-Tyr125/136]:a-synuclein with nitrosylated tyrosine 39 [N-aSyn-Tyr39]
ratio) is significantly higher in patients with early PD ( p< 0.01). These observations lead to the hypothesis that
evaluating nitrosative stress through enhanced levels of 3-nitrotyrosine proteins in serum and CSF without changes
in nitroalbumin, together with the profile of tyrosine nitrosylation of serum aSyn characterized by dominant
nitrosylation of Tyr125/136, could serve for the diagnosis of sporadic PD. Antioxid. Redox Signal. 19, 912–918.
Introduction
Oxidative stress is considered as a pathogenic mech-anism in Parkinson’s disease (PD) (6). Nitrosylation is a
type of oxidative stress where modifications of proteins and
free amines are due to excess of nitric oxide. Nitrosylation of
tyrosine (Tyr) leading to 3-nitrotyrosine proteins or free 3-ni-
trotyrosine is the most prominent change. Excess nitrosylation is
recognized as a salient feature of a-synucleinopathies such as
PD, where 3-nitrotyrosine proteins such as nitrosylated neu-
rofilaments and a-synuclein (aSyn) are detected in brain
aggregates (5). However, levels of 3-nitrotyrosine proteins or
free 3-nitrotyrosine in serum and cerebrospinal fluid (CSF) of
patients with PD have not been studied, and the presence of
free 3-nitrotyrosine deserves investigation, because it is
known to be neurotoxic for striatal neurons (7).
Regarding aSyn, this protein represents a main component
of Lewy bodies, the hallmarks of PD, and mutations in aSyn
have been linked to familial PD. This protein contains 140
amino acids with four tyrosine residues (Tyr39 at amine ter-
minus, and Tyr125, Tyr133, and Tyr136 at carboxyl terminus),
which are readily accessible for modification by nitrating
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agents. These residues can be differentially nitrosylated
leading to different functional effects (4). Although parkin-
sonian nitrosylation of aSyn is suspected to occur in brain
tissue, this protein can also be detected in CSF and blood (2).
The presence of aSyn in CSF is already known, but aSyn ni-
trosylation has not been studied. In contrast, nitro-a-synuclein
(N-aSyn) has been detected in blood mononuclear cells of
patients with PD (9), although serum levels are not known.
The objectives of this study were (i) to determine in serum and
CSF of patients with PD and control subjects the presence of
3-nitrotyrosine proteins and free 3-nitrotyrosine, markers for
protein and amine nitrosylation, and (ii) to discern the effects
of nitrosylation on serum and CSF aSyn.
Results and Discussion
First, we verified that the main clinical characteristics were
similar between the PD and control groups, except for hyper-
tension, which was more frequent in patients ( p< 0.01). Then,
we evaluated the presence of nitrosative stress in blood and
CSF of patients with PD, and we quantified the serum levels of
3-nitrotyrosine proteins through an enzyme-linked immuno-
sorbent assay (ELISA). Regarding serum, 3-nitrotyrosine pro-
tein levels were found to be significantly enhanced in serum of
patients relative to control subjects (PD patients= 70.6– 4.7 nM;
controls= 48.3– 6.8 nM; t= 2.67, p< 0.01). Taking into account
the Hoehn-Yahr stages of the disease, 3-nitrotyrosine protein
levels were found to be enhanced in all stages, but significant
differences were only found in early or Hoehn-Yahr-stage-1
and 2 patients (Fig. 1). Nitroalbumin was also quantified, and
differences were not found (PD patients= 1.6– 0.1lg/ml;
controls= 1.4– 0.4lg/ml).
Regarding CSF, 3-nitrotyrosine protein levels were found to
be significantly enhanced in CSF of patients relative to controls
(PD patients=4.6–1.1 nM; controls=0.9–0.4 nM; t=3.1,
p<0.004). 3-nitrotyrosine protein levels were found to be sig-
nificantly enhanced in the Hoehn-Yahr-stage-1 and 2 patients
relative to controls and advanced patients (one-way analysis
of variance [ANOVA] group effect, F3, 54=3.24, p<0.029; stage
1, p<0.05; stage 2, p<0.01 vs. controls; Fig. 1). Regarding
nitroalbumin, the differences were not found to be significant
(PD patients=0.09–0.02lg/ml; controls=0.02–0.01lg/ml).
The Tibbling-Link index was lower than 0.7 in every patient
with PD, discarding that the increase in CSF 3-nitrotyrosine
proteins was caused by enhanced blood levels.
Since nitrosylative stress can also yield free nitrosylated
amines such as 3-nitrotyrosine (7), we evaluated its presence
in serum and CSF with mass spectrometry. 3-nitrotyrosine
(retention time = 9.19 to 9.59 min) was not detected in any
patient, and only several unknown compounds with different
retention times were observed in the MS spectra (Fig. 2).
The findings suggested that nitrosylation was quite selec-
tive, affecting 3-nitrotyrosine proteins other than albumin.
Then, we decided to evaluate which proteins were ni-
trosylated. For this purpose, immunoblots of serum needs
previous depletion of serum albumin or immunoprecipitation
of proteins of interest, and since usual techniques are dena-
turalizing and distort the physiologically oligomeric structure
of many proteins, we used a low-denaturalizing method
based on one-step filtration. This method allowed obtaining a
filtrate containing proteins lower than 60 kDa. Surprisingly, it
led to the detection of a single protein band at *56 kDa in
serum from patients and controls, after anti-3-nitrotyrosine
(Fig. 3A). Of note is that a band around 56 kDa is characteristic
of tetrameric aSyn, the physiological form of endogenous
aSyn (1). Hence, we also tested an anti-aSyn monoclonal an-
tibody, and similar*56-kDa blot bands were observed in the
same patients (Fig. 3B). Hence, the immunoblot signal of
3-nitrotyrosine proteins (< 60 kDa) seems to correspond to
N-aSyn. In fact, if we used more denaturalizing methods such
as immunoprecipitation of 3-nytrotyrosine proteins, which
breaks cross-linking of Tyr residues, immunoblots yielded not
only *56-kDa bands but also *28- and *14-kDa bands in
most subjects (Fig. 4). However, when we measured the levels of
total aSyn in serum through ELISA, no differences were found
(PD patients=327–45 pg/ml, controls=425.8–65 pg/ml). ELI-
SA levels of 3-nitrotyrosine proteins in filtered serum were
similar in patients and controls (PD patients = 2.3 – 0.7 nM,
controls = 3.1 – 1.1 nM). Besides, after measuring the intensity
of bands of 3-nitrotyrosine and aSyn in blots of filtered serum,
no differences were observed between patients with PD and
controls (data not shown). All these findings indicate that
serum nitrosative stress in PD increases the levels of 3-
nitrotyrosine proteins (> 60 kDa) other than N-aSyn and ni-
troalbumin. These proteins are under study in our laboratory.
Regarding CSF, blots of filtered CSF did not reveal the
presence of 3-nitrotyrosine proteins, indicating that CSF aSyn
was not nitrosylated. When we measured the levels of total
aSyn in CSF through ELISA, the levels were found to be sig-
nificantly lower in patients (25.5 – 3 pg/ml) relative to con-
trols (33.1 – 2.3 pg/ml, p < 0.05), in accordance with others (8).
Hence, aSyn is present in CSF of patients with PD at lower
values than normal, but its nitrosylated form is not detected.
To further characterize the effects of nitrosative stress on
serum N-aSyn, and taking into account that the physiologi-
cally tetrameric structure of N-aSyn was very well preserved
with our method of albumin removal, and Tyr residues of
N-aSyn can be differentially nitrosylated leading to different
functional effects (9), we evaluated the sites of Tyr nitrosyla-
tion of the molecule. Two monoclonal antibodies (mAbs) were
used for detecting nitrosylated aSyn at Tyr residues of the
carboxyl terminus (a-synuclein with nitrosylated tyrosines
125 and 136 [N-aSyn-Tyr125/136] or nSyn12 mAb), and of
the amine terminus (a-synuclein with nitrosylated tyrosine 39
Innovation
We report for the first time the presence of selective
nitrosylation stress in serum and cerebrospinal fluid of
patients with early Parkinson’s disease (PD), characterized
by excess of 3-nitrotyrosine proteins other than ni-
troalbumin, without free 3-nitrotyrosine. We also detected
nitrosative changes in serum nitro-a-synuclein (N-aSyn),
characterized by an altered profile of tyrosine (Tyr) ni-
trosylation. Thus, the intensity of nitrosylation of Tyr125/
136 residues is enhanced, and that of the Tyr39 site is re-
duced, and the ratio between both parameters is higher in
patients with early PD relative to controls. Our observa-
tions lead to the hypothesis that evaluating nitrosative
stress through enhanced levels of 3-nitrotyrosine proteins
other than nitroalbumin, together with the profile of ty-
rosine nitrosylation of serum N-aSyn, could serve for the
diagnosis of sporadic PD.
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[N-aSyn-Tyr39] or nSyn14 mAb). The intensity of blot bands
(Scion units) was measured at each Hoehn-Yahr stage, and
two-way ANOVA revealed a significant interaction effect
( p< 0.0001, Fig. 5). The intensity of nitrosylation at Tyr125/
136 was enhanced in the Hoehn-Yahr-stage-1 and 2 patients
relative to advanced patients ( p< 0.01; Newman-Keuls) as
well as controls (stage 1, t = 2.48, p< 0.02; stage 2, t = 2.6,
p < 0.01) as shown in Figure 5. The intensity of the N-aSyn-
Tyr39 band was found to be significantly reduced in stage-1
patients relative to controls (t= 2.1, p< 0.05; Fig. 5). Besides,
after comparing the two types of immunoblot bands at each
stage, the intensity of the N-aSyn-Tyr125/136 band was sig-
nificantly higher than that of N-aSyn-Tyr39 in patients with
early disease (stage 1, t= 4.5, p< 0.001; stage 2, t = 3.18,
p < 0.01). The data also indicate that disease progression leads
to recovery of the control intensity of the N-aSyn-Tyr125/136
and N-aSyn-Tyr39 bands.
The ratio defined as the intensity of the N-aSyn-Tyr125/136
band between the intensity of the N-aSyn-Tyr39 band was
also quantified as another index of nitrosylation. This ratio
was significantly elevated in patients with early PD versus
advanced patients and controls ( p < 0.001; Fig. 6A). All pa-
tients at stage 1, and 18 out of 21 patients at stage 2 (90%),
showed a ratio higher than 1.6, whereas this ratio was ever
observed to be lower than 1.6 in control subjects and ad-
vanced patients (Fig. 6B). This value can be considered as a
limit between patients with early PD and controls.
Finally, to further analyze N-aSyn properties, simple linear
regression analyses between the intensity of the N-aSyn-
Tyr125/136 or N-aSyn-Tyr39 bands and clinical characteristics
were carried out. No significant regressions were observed in
controls, and the intensity of the N-aSyn-Tyr125/136 or N-aSyn-
Tyr39 bands were not affected by any clinical feature. However,
in patients with PD, the N-aSyn-Tyr125/136 intensity and
N-aSyn-Tyr125/136:N-aSyn-Tyr39 ratio were found to be re-
lated with Hoehn-Yahr stage (N-aSyn-Tyr125/136, R2=0.258,
T=2.3, p<0.05; ratio, R2=0.13, T=2.89, p<0.004). Linear regres-
sion of all individual N-aSyn-Tyr125/136:N-aSyn-Tyr39 ratios of
patients with PD are shown in Figure 5B. It is worth noting that
antiparkinsonian medication (levodopa, dopaminergic agonists,
and rasagiline), use of statins or aspirin, or vitamin A/E sup-
plements were devoid of effects on these progressive changes.
In summary, our results show for the first time that there
are indicators of selective nitrosylation stress of proteins in
serum and CSF of patients at early stages of PD, characterized
by excess of 3-nitrotyrosine proteins (> 60 kDa) other than
FIG. 1. Levels of 3-nitrotyrosine and nitroalbumin in PD fluids. Levels of 3-nitrotyrosine proteins and nitroalbumin in
serum (A) and CSF (B) of patients with PD at the four Hoehn-Yahr stages, and control subjects. Mean – SEM, *p< 0.05,
**p< 0.01 versus controls (serum, stage 1, t= 2.2, p < 0.05, stage 2, t= 2.6, p < 0.01; CSF, stage 1, t= 2.39, p< 0.02, stage 2, t= 2.9,
p < 0.008; Student’s t-test). CSF, cerebrospinal fluid; PD, Parkinson’s disease.
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nitroalbumin, and the absence of free 3-nitrotyrosine. Free 3-
nitrotyrosine is toxic for striatal neurons in the experimental
models of PD, but this nitrated amine seems not to participate
on human PD. The findings also confirm that there is a
physiological level of protein nitrosylation in serum (5).
Among 3-nitrotyrosine proteins, N-aSyn was detected in se-
rum, not CSF, of patients and controls. Of note is that N-aSyn
is an abundant component of the Lewy bodies. The protein
aSyn was detected in both serum and CSF, where levels were
found to be lower in patients than controls (8), and as a tet-
ramer (*56 kDa), its actual physiological shape (1).
Serum N-aSyn levels were not modified in PD, but our study
is the first one reporting a selective change in nitrosylation of
the Tyr sites of serum aSyn, characterized by dominant ni-
trosylation of Tyr125/136 residues and low nitrosylation of the
Tyr39 site. In other words, the carboxyl terminus tyrosines of
the molecule showed higher nitrosylation than the amine ter-
minus one in patients with early PD. The ratio between the blot
intensity of both parameters (N-aSyn-Tyr125/136:N-aSyn-
Tyr39 ratio) was significantly higher in patients with early PD
relative to controls and advanced patients. Nitrosative effects
are progressively reduced over time, and medication does not
contribute to these changes.
Taken together, the findings suggest the presence of protein
nitrosative stress in serum and CSF of Hoehn-Yahr-stage-1 and
2 patients, leading to the selective increase of 3-nitrotyrosine
proteins other than nitroalbumin. We propose that evaluating
nitrosative stress through enhanced levels of 3-nitrotyrosine
proteins in serum and CSF without changes in nitroalbumin,
together with the profile of Tyr nitrosylation of serum N-aSyn,
could serve for the diagnosis of sporadic PD.
Notes
Study participants
Patients suffering from PD and clinically and underwent
single-photon-emission computerized tomography (SPECT)-
based diagnosis were included in the study. Patients were
FIG. 2. Mass spectrometry
(MS) spectra of 3-nitroty-
rosine standard 1ppm, and
representative MS spectra of
serum and CSF of a patient
with PD. The transitions for
nitrotyrosine are 227.1/181.0,
227.1/133.1, and 227.1/116.9,
with retention times from
9.19 to 9.59 min.
FIG. 3. Representative im-
munoblots of 3-nitrotyrosine
proteins and a-synuclein of
PD patients. Immunoblot
analysis of serum 3-nitrotyr-
osine proteins (A) and serum
a-synuclein (B) in the same
patients with PD (n=9). Similar
blot signals were obtained, with
bands located to *56 kDa of
molecular mass. These blots
were done after serum filtration
and removal of proteins higher
than 60 kDa, including serum
albumin.
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classified according to the Hoehn-Yahr stages, UPDR scales,
and the duration of PD in years. The duration of PD was
calculated on the basis of the year when first symptoms were
reported by the patient. All participants were nonsmokers or
nonalcohol drinkers. Control subjects were recruited from
either patients’ relatives or volunteers without any neuro-
logical disorder and subjected to intradural anesthesia for
traumatologic surgery in Macarena Hospital. Individuals
presenting with any of renal, liver, and cardiac dysfunction,
malabsorption, autoimmune diseases, AIDS, diabetes melli-
tus, rheumatoid arthritis, and infectious conditions (oxidative
stress markers in peripheral blood may be altered in such
conditions) were excluded from both PD and control groups.
Clinical information was gathered from each patient: age, sex,
body weight, hypertension, dyslipidemia, fasting blood su-
gar, coffee drinking, smoking, taking of vitamin A/Vitamin E
supplement, statins, and aspirins, daily levodopa dose, type
and dose of dopamine agonists, and rasagiline (3).
Blood and CSF collection and biochemical measures
Five ml of blood was collected, after cephalic vein puncture,
in gel-coated tubes to induce blood coagulation, and to obtain
serum (BD Vacuotainer). Serum was centrifuged at 2500 rpm
during 10 min, and then it was aliquoted, coded, and frozen at
- 80C. CSF was collected by using lumbar puncture. Five ml of
CSF was collected and stored in polypropylene tubes (Euro-
tube), and rapidly aliquoted, coded, and frozen at - 80C for
further analyses. A 1-ml collection in a glass tube was em-
ployed to observe the absence of traumatic puncture and to
quantify red cells before storing (3). CSF with excess of red cells
was discarded (> 500 red cells/ll). For measuring 3-nitrotyr-
osine proteins and aSyn, commercial kits were used (Oxiselect
Nitrotyrosine kit; Cell Biolabs, Inc., Human aSyn Elisa Kit;
BlueGene Biotech), following the manufacturers’ instructions.
Filtered serum and CSF were not diluted. Finally, the Tibbling-
Link index was calculated as already reported (3).
Mass spectrometry
Chromatographic separation was performed using a
PelkinElmer Series 200 high-performance liquid chromatog-
raphy (HPLC) system coupled to an Applied Biosystems
QTRAP LC/MS/MS system consisting of a hybrid triple-qua-
druple linear ion-trap (QqQlit) mass spectrometer equipped
with an electrospray ion source. HPLC analyses were per-
formed on a 100· 2.1-mm Xselect HSS PFP reversed-phase
column with a particle size of 2.5lm (Waters). The flow rate
was 0.2 ml min-1. Chromatographic separation was performed
using a binary gradient consisting of (A) water and (B) meth-
anol. Both components contained 0.05% trifluoroacetic acid (v/
v). The elution profile was 10% B (1 min) and a linear gradient
up to 90% B (9 min), 90% B (5 min), and followed by 5 min of re-
equilibration of the column before the next run. The injection
volume was 20ll. Multiple Reaction Monitoring (MRM) ex-
periment was applied where the precursor ions and fragment
ions were monitored at Q1 and Q3, respectively. The transitions
for nitrotyrosine are 227.1/181.0, 227.1/133.1, and 227.1/116.9.
For HPLC-ESI-MS/MS analyses, the mass spectrometer was
set to the following optimized tune parameters: curtain gas 20
psi, ion spray voltage 5500 V, and source temperature 350C.
Albumin removal and western blotting
A low-denaturalizing method was used for removing al-
bumin from serum and CSF samples, the most abundant pro-
tein, based on filtration with Amicon Ultra 50K (Millipore). We
have observed that one-step filtration (following the manu-
facturer’s instructions) allows obtaining a filtrate with mole-
cules lower than 60 kDa, and hence albumin is depleted
without the need of magnetic beads or immunoprecipitation.
This method proved to be crucial, because the physiological
tetrameric structure of serum aSyn was not distorted. Serum
and CSF samples were then lysed in 10% glycerol, 137 mM
NaCl, and 20 mM Tris–HCl, pH 7.5, containing peptidase in-
hibitors (1lg/ml aproteinin and leupeptin, and 1 mM PMSF).
The protein levels were quantified by using the Bradford
method. Samples were boiled, and aliquots containing 15lg of
protein each were subjected to SDS/polyacrylamide gel elec-
trophoresis. Proteins were transferred electrophoretically to
PVDF membranes. Immunolabeling was conducted with pri-
mary antibodies for 3-nitrotyrosine (monoclonal antibody to
nitrotyrosine; Hycult Biotech), a-synuclein (monoclonal anti-a-
synuclein antibody Syn211; Sigma-Aldrich), nitrosylated aSyn
at Tyr residues 125/136 (anti-nitro-a/b-synuclein antibody,
nSYn12; Millipore), and nitrosylated aSyn at tyrosine 39 (anti-
nitro-a/b-synuclein antibody Tyr39, nSYn14; Millipore).
Primary antibodies were detected with peroxidase-linked
secondary antibodies (Santa Cruz Biotechnology), with en-
hanced chemiluminescence (ECL; Amersham, GE HealthCare)
and autoradiography. Band densities of the resulting autora-
diograms were quantified by using the Scion Image program
FIG. 4. Representative immunoblots of 3-nitrotyrosine
proteins in 2 controls and 2 patients with PD, after im-
munoprecipitation (PureProteome Protein G Magnetic
Bead System; Millipore). Three bands of proteins lower than
60 kDa of molecular mass can be observed, at *56, *28, and
*14 kDa. The denaturalizing treatment of samples is known
to break cross-linking between tyrosine residues of proteins. If
the*56-kDa band was observed to contain tetramers of aSyn,
it seems that*28- and*14-kDa bands would contain dimers
and monomers of aSyn, respectively. aSyn, a-synuclein.
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for PC (NIH). Values are given as the intensity of bands in
arbitrary Scion Units. Finally, immunoprecipitation was used
at the beginning of the study for albumin removal, based on the
PureProteome Protein G Magnetic Bead System (Millipore),
following the manufacturer’s instructions. This method proved
to be more denaturalizing than western blotting after filtration.
Statistical analysis and ethics
We enrolled 54 patients, comprising four Hoehn-Yahr
stages (stage 1, n= 13; stage 2, n = 21; stage 3, n = 10; stage 4,
n = 10), and 40 controls. Differences in the nitrosylation
markers and clinical characteristics between the PD and
control groups were analyzed by the w2 test or Student’s t-test
(independent samples). Comparisons between clinical char-
acteristics and nitrosylation markers within patients at dif-
ferent PD stages were analyzed by one-way ANOVA,
followed by the Student’s t-test. When two factors were
studied, two-way ANOVA was used, followed by Newman–
Keuls’ test or Student’s t-test when appropriate. Two groups
were compared with the Student’s t-test. If needed, normali-
zation was verified with the Shapiro–Wilk test. In patients
and controls, simple regression analysis was used for
searching for correlations between nitrosylation markers and
clinical factors. Informed consent forms under a protocol ap-
proved by the University of Seville and Macarena Hospital
internal ethics and scientific boards were obtained from all the
subjects, and the subjects’ consent was obtained according to
the Declaration of Helsinki (BMJ 1991; 302: 1194).
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N-aSyn-Tyr125/136¼ a-synuclein with nitrosylated
tyrosines 125 and 136






FIG. 6. Values of ratios of nitrosylation at Tyr125/136 residues between nitrosylation at Tyr39 site of a-synuclein. (A)
Values of the N-aSyn-Tyr125/136: N-aSyn-Tyr39 ratio in controls and patients (Hoehn-Yahr stages 1 to 4). One-way ANOVA
revealed a significant stage effect (F3, 53= 4.14, p< 0.011). Mean– SEM. **p< 0.01 versus ratio in controls (stage 1, t= 6.7,
p< 0.0001; stage 2, t= 2.73, p< 0.01). (B) Individual N-aSyn-Tyr125/136:N-aSyn-Tyr39 ratios in controls and patients. All patients
at stage 1 and 90% (18/21) of stage-2 patients showed a ratio higher than 1.6, while this ratio was ever observed to be lower than
1.6 in controls and advanced patients. The regression line of patients with PD is represented.
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